MINNEAPOLIS, March 28, 2003 – Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration approval of the InSync Marquis™ cardiac […]
Use of early coronary artery bypass grafting after acute myocardial infarction is influenced by state, hospital and payer characteristics, however, timing of […]
The aim of this study was to assess the safety and efficacy of the fully repositionable and retrievable Direct Flow Medical (DFM) valve for the treatment of mitral annuloplasty failure.
